| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/14/2002 | WO2001030802A3 Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies |
| 02/14/2002 | WO2001025489A3 Diagnostic and therapeutic uses for a gene differentially expressed in prostate cancer |
| 02/14/2002 | WO2001021771A3 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 02/14/2002 | WO2001014418A3 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 02/14/2002 | WO2000073337A9 Polymer conjugates of hedgehog proteins and uses |
| 02/14/2002 | WO2000068258A3 Compounds exhibiting an antibiotic activity |
| 02/14/2002 | WO2000044908A9 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins |
| 02/14/2002 | WO2000009552A9 Secreted proteins and polynucleotides encoding them |
| 02/14/2002 | WO1997020938A3 Cells with hybrid receptor and gene construct which can be controlled by said hybrid receptor, and use of said cells in gene therapy |
| 02/14/2002 | WO1995029669A3 Multifunctional ligand for use as a diagnostic or therapeutic pharmaceutical |
| 02/14/2002 | US20020019992 Transgenic non-human mammals with progressive neurologic disease |
| 02/14/2002 | US20020019519 KIAA0551 polynucleotides and polypeptides use |
| 02/14/2002 | US20020019429 Antiarthritic agents; osteoporosis |
| 02/14/2002 | US20020019403 Inhibit amyloid protein deposits |
| 02/14/2002 | US20020019363 Viricides for hepatitis c |
| 02/14/2002 | US20020019362 Treatment of tumors with genetically engineered herpes virus |
| 02/14/2002 | US20020019360 Treatment for cardiovascular disease |
| 02/14/2002 | US20020019359 Oligonucleotide with a base sequence complementary to a target portion of a nucleic acid encoding angiogenin |
| 02/14/2002 | US20020019358 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| 02/14/2002 | US20020019352 Stable, active, human ob protein compositions and methods |
| 02/14/2002 | US20020019351 Treatment of skeletal disorders |
| 02/14/2002 | US20020019350 Targeted angiogenesis |
| 02/14/2002 | US20020019349 Hypotensive, antiischemic and wound healing agents |
| 02/14/2002 | US20020019347 Amino acid sequences of the peptides |
| 02/14/2002 | US20020019346 Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| 02/14/2002 | US20020019345 Administering to a patient having implant an effective amount of antagonist of CCR5 (chemokine receptor 5) function, to inhibit graft rejection, antagonist selected from small organic molecules, peptides, proteins, peptidomimetics |
| 02/14/2002 | US20020019343 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
| 02/14/2002 | US20020019341 Modulation of systemic memory T cell trafficking |
| 02/14/2002 | US20020019340 Polymer stabilized neuropeptides |
| 02/14/2002 | US20020019336 Sustained release drug compositions |
| 02/14/2002 | US20020019335 Methods of investigating, diagnosing, and treating amyloidosis |
| 02/14/2002 | US20020019334 Nutritional intervention composition for enhancing and extending satiety |
| 02/14/2002 | US20020019333 Preventive and therapeutic compositions for drug induced nephropathy and hepatopathy |
| 02/14/2002 | US20020019332 Method of inducing apoptosis in b-lymphocytes |
| 02/14/2002 | US20020019331 Enhancing an immune response to a human self tumor antigen, by immunizing a human being with a foreign protein homologous to human self tumor antigen which is a protein expression product of an overexpressed human oncogene |
| 02/14/2002 | US20020019043 Treating inflammatory bowel disease in humans; obtain human, administer drug, monitor for reduction in side effects from gastrointestinal disorder |
| 02/14/2002 | US20020019040 Apoptin-associating protein |
| 02/14/2002 | US20020019030 25324, 50287, 28899, 47007, and 42967 transferase family members and uses therefor |
| 02/14/2002 | US20020019027 Protein for use in the prevention and treatment of cancer; antitumor agents; anticarcinogenic agents |
| 02/14/2002 | US20020019026 Nucleotide sequences coding preferential polypeptide for use in te detection and treatment of cancer, psychological and nervous system disorders; for use in gene therapy |
| 02/14/2002 | US20020019025 Purification of fibrinogen from fluids by precipitation and hydrophoic chromatography |
| 02/14/2002 | US20020019020 Methods for treating cardiovascular disorders |
| 02/14/2002 | US20020019008 Administering to the mammal a formulation comprising a an SMR1 (submandibular rat protein) protein, or its maturation product or derivatives to prevent or treat the diseases caused by mineral ion imbalance |
| 02/14/2002 | US20020019000 Polynucleotides coexpressed with matrix-remodeling genes |
| 02/14/2002 | US20020018995 Detecting brain disorders; obtain sample tissue, monitor tau mutant isoform duplications in cell, compare to wild type, amplification in tau mutant isoforms indicates brain disorders |
| 02/14/2002 | US20020018988 In silico screening |
| 02/14/2002 | US20020018808 Vaccines against sterols |
| 02/14/2002 | US20020018786 Administering neurotoxin |
| 02/14/2002 | US20020018782 Binding to antibodies; prophylaxis, therapy of infections |
| 02/14/2002 | US20020018781 Drugs, vaccines |
| 02/14/2002 | US20020018778 Passive desensitization |
| 02/14/2002 | US20020018776 Method of treating graft rejection using inhibitors of CXCR3 function |
| 02/14/2002 | US20020018775 Complexing; separation; gene therapy |
| 02/14/2002 | US20020018773 Using lipase |
| 02/14/2002 | US20020018772 Super absorption coenzyme Q10 |
| 02/14/2002 | US20020018768 Control of gene expression |
| 02/14/2002 | US20020018763 Blood disorders; using genetically engineered polypeptide |
| 02/14/2002 | US20020018751 Cellular and serum protein anchors for diagnostic imaging |
| 02/14/2002 | US20020018750 Anticancer agents |
| 02/14/2002 | US20020018749 High avidity polyvalent and polyspecific reagents |
| 02/14/2002 | US20020017305 Method of restoring endothelium of cornea |
| 02/14/2002 | DE10038699A1 Mittel zur Verringrung der Abstoßungsreaktionen bei Transplantaten Means for Verringrung of rejection reactions in transplants |
| 02/14/2002 | DE10038640A1 Präparat mit gefäßschützender und antioxidativer Wirkung sowie dessen Verwendung Preparation with vascular protective and antioxidant activity and its use |
| 02/14/2002 | DE10037861A1 Composition for treating malignant disease, useful especially for cervical carcinoma, contains agent that inhibits activity of nucleolin |
| 02/14/2002 | DE10037389A1 Verfahren und Vorrichtung zur Anreicherung und Stabilisierung von konjugierten Oestrogenen aus Stutenharn Method and apparatus for concentrating and stabilizing conjugated estrogens from Stutenharn |
| 02/14/2002 | DE10036871A1 Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe Dispersions for the formulation of poorly soluble drugs or little |
| 02/14/2002 | DE10032296A1 Composition for cancer prophylaxis comprises substances that promote embryonic cell growth |
| 02/14/2002 | CA2774959A1 Method of using diketopiperazines and composition containing them |
| 02/14/2002 | CA2423519A1 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | CA2419132A1 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway |
| 02/14/2002 | CA2419060A1 Indole compounds useful for the treatment of cancer |
| 02/14/2002 | CA2419052A1 Potential growth factors from the human tumour cell line ht1080 |
| 02/14/2002 | CA2418995A1 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | CA2418960A1 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
| 02/14/2002 | CA2418950A1 Soluble zcytor 11 cytokine receptors |
| 02/14/2002 | CA2418936A1 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis |
| 02/14/2002 | CA2418913A1 Peptide mimetics |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418386A1 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| 02/14/2002 | CA2418154A1 Treatment of hepatitis c with thymosin and pegylated interferon |
| 02/14/2002 | CA2418144A1 Urocortin proteins and uses thereof |
| 02/14/2002 | CA2418085A1 Treatment of hepatitis c with thymosin, interferon and ribavirin |
| 02/14/2002 | CA2418083A1 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | CA2418023A1 Combinations of dalfopristine/quinupristine with cefpirome |
| 02/14/2002 | CA2418014A1 Immunotherapy for chronic myelocytic leukemia |
| 02/14/2002 | CA2417982A1 Manipulation of arterial-venous identity |
| 02/14/2002 | CA2417915A1 Her-2/neu fusion proteins |
| 02/14/2002 | CA2417866A1 Compositions and methods for the therapy and diagnosis of colon cancer |
| 02/14/2002 | CA2417769A1 Drug metabolizing enzymes |
| 02/14/2002 | CA2417767A1 Peptides presented by cells |
| 02/14/2002 | CA2417707A1 Sid.rtm. nucleic acids and polypeptides selected from a pathogenic strain of hepatitis c virus and applications thereof |
| 02/14/2002 | CA2417676A1 Sequences for integrin alpha-8 |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417368A1 Suppressor gene |
| 02/14/2002 | CA2417240A1 Method and composition for immunization using mixed pools of mutated nucleic acids or peptides |
| 02/14/2002 | CA2417225A1 Electro-powder |
| 02/14/2002 | CA2417214A1 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| 02/14/2002 | CA2416982A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/14/2002 | CA2416890A1 Therapeutic anti-melanoma compounds |
| 02/14/2002 | CA2416531A1 Compositions for preventing urinary calculus |